Kazia Therapeutics Launches Public Offering to Fund Paxalisib Trials

The offering includes ADSs, each representing 500 ordinary shares, alongside Series A and Series B warrants. These warrants carry exercise prices set at 115% and 125% of the initial offering price, respectively. Their expiration is tied to specific clinical milestones: the Series A warrants expire following the Stage IV triple-negative breast cancer data readout anticipated in late 2027, while the Series B warrants align with the HR+/HER2- data readout expected in the first half of 2028.

Leerink Partners and Guggenheim Securities are serving as joint bookrunning managers for the transaction. Proceeds are earmarked primarily for the advancement of paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway. Beyond its breast cancer studies, Kazia continues to evaluate the drug for brain metastases and other forms of cancer, supported by previous Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. The completion of the offering remains subject to prevailing market conditions.